ZHEJIANG GARDEN BIOPHARMACEUTICAL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.67 CNY | -0.19% |
|
-0.28% | -9.65% |
| Sales 2022 | 1.42B 196M | Sales 2023 | 1.09B 151M | Capitalization | 6.49B 896M |
|---|---|---|---|---|---|
| Net income 2022 | 384M 53.04M | Net income 2023 | 192M 26.52M | EV / Sales 2022 | 5.58 x |
| Net cash position 2022 | 22.52M 3.11M | Net Debt 2023 | 177M 24.44M | EV / Sales 2023 | 6.09 x |
| P/E ratio 2022 |
20.6
x | P/E ratio 2023 |
36.9
x | Employees | 849 |
| Yield 2022 |
0.97% | Yield 2023 |
-
| Free-Float | 61.9% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.19% | ||
| 1 week | -0.28% | ||
| Current month | +9.77% | ||
| 1 month | +11.15% | ||
| 3 months | -3.00% | ||
| 6 months | -0.56% | ||
| Current year | -9.65% |
1 week
9.95
11.20
1 month
9.3511.20
Current year
7.5811.81
1 year
7.5813.09
3 years
7.5821.05
5 years
7.5821.65
10 years
1.8525.59
| Managers | Title | Age | Since |
|---|---|---|---|
Huan Zheng Ma
CEO | Chief Executive Officer | 59 | 99-12-31 |
Chun Hua Wu
DFI | Director of Finance/CFO | 48 | 16-04-28 |
Quan Heng Yu
BRD | Director/Board Member | 58 | 06-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yi Ping Shao
BRD | Director/Board Member | 61 | 21-01-31 |
Jian Miao Yan
BRD | Director/Board Member | 58 | 21-01-31 |
Qin Xiang Shao
BRD | Director/Board Member | 70 | 03-10-09 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.10% | 12 M€ | -16.71% | - | |
| 0.00% | 34 M€ | +1.25% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 10.67 | -0.19% | 16,091,930 |
| 24-04-18 | 10.69 | -4.55% | 24,691,240 |
| 24-04-17 | 11.2 | +1.91% | 36,366,490 |
| 24-04-16 | 10.99 | +8.28% | 39,466,510 |
| 24-04-15 | 10.15 | -5.14% | 21,274,590 |
End-of-day quote Shenzhen S.E., April 18, 2024
More quotes
Zhejiang Garden Biopharmaceutical Co Ltd, formerly Zhejiang Garden Bio-chemical High-tech Co Ltd, is a China-based company mainly engaged in the research, development, production and sales of vitamin D3 upstream and downstream products. The Company's vitamin products mainly include lanolin cholesterol, food and pharmaceutical grade vitamin D3, 25-hydroxyvitamin D3 and others. The Company also focuses on the research and development, production and sales of high-tech barrier preparations in the fields of cardiovascular, nervous system and other chronic diseases. The other products of the Company include Levofloxacin Tablets, Doxofylline Injection, Lipoic Acid Injection, Escitalopram Oxalate Tablets and others.
Sector
Pharmaceuticals
Calendar
2024-05-06
- Annual General Meeting
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -9.65% | 797M | |
| +20.91% | 43.54B | |
| +16.96% | 21.74B | |
| +9.05% | 13.53B | |
| +7.98% | 13.02B | |
| +33.80% | 11.28B | |
| -11.05% | 6.99B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +6.64% | 5.09B |
- Stock Market
- Equities
- 300401 Stock
